Audiological findings in patients treated with radio- and concomitant chemotherapy for head and neck tumors

Radiation Oncology

Volumn 4, Issue 1, 2009, Pages

  Dell'Aringa, Ana H B ^a   Isaac, Myrian L ^b   Arruda, Gustavo V ^c   Esteves, Maria C B ^a   Dell'Aringa, Alfredo R ^a   Júnior, José L S ^d   Rodrigues, Alexandre F ^e  

^a Departament of Otorhinolaryngology of FAMEMA's General Hospital   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Radiotherapy of FAMEMA's General Hospital   (Brazil)

^d FAMEMA   (Brazil)

^e Marília ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEAD AND NECK CANCER; HEAD AND NECK TUMOR; HEARING ACUITY; HEARING DISORDER; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; RADIATION DOSE; RADIATION RESPONSE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; AGED; ARTICLE; HEARING TEST; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RADIOTHERAPY;

AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HEARING DISORDERS; HEARING TESTS; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 71049149718     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-4-53     Document Type: Review

References (14)

1. Pearson SE, Meyer AC, Adams GL, Ondrey FG. Decreased hearing after combined modality therapy for head and neck cancer. Am J Otolaryngol 2006, 27(2):76-80. 10.1016/j.amjoto.2005.07.008, 16500467.
2. American Speech-Language-Hearing Association (ASHA) Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 1994, 36(suppl 12):11-19.
3. Chen WC, Jackson A, Budnick AS, Pfister DG, Kraus DH, Hunt MA, Stambuk H, Levegrun S, Wolden SL. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 2006, 15;106(4):820-9.
4. Herrmann F, Dörr W, Müller R, Herrmann T. A prospective study on radiation-induced changes in hearing function. Int J Radiat Oncol Biol Phys 2006, 5; 65(1):1338-44.
5. Bhandare N, Antonelli PJ, Morris CG, Malayapa RS, Mendenhall WM. Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys 2007, 1;67(2):469-79.
6. Low WK, Tho ST, Wee J, Fook-Chong SMC, Wang DY. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. Clin Oncol 2006, 26;24(12):1904-9.
7. Stöhr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E, Beck JD. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest 2005, 23(3):201-7. 10.1081/CNV-200055951, 15945505.
8. Biro K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I. Characteristics and Risk Factors of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients Detected by Distorsion Product Otoacoustic Emission. Oncology 2006, 70(3):177-84. 10.1159/000093776, 16757924.
9. Ho WK, Wei WI, Kwong DL, Sham JST, Tai PTH, Yuen APW, Au DKK. Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: A prospective study. Head Neck 1999, 21(6):547-53. 10.1002/(SICI)1097-0347(199909)21:6<547::AID-HED8>3.0.CO;2-Y, 10449671.
10. Honoré HB, Bentzen SM, Moller K, Grau C. Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. Radiother Oncol 2002, 65:9-16. 10.1016/S0167-8140(02)00173-1, 12413669.
11. Pan CC, Eisbruch A, Lee JS, Snorrason RM, Haken RK, Kileny PR. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 2005, 61:1393-1402. 15817342.
12. Blakley BW, Gupta AK, Myres SF, Schwan S. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 1994, 120:541-6.
13. Powis GD, Hacker MP. The Toxicity of Anticancer Drugs. 1991, 269-283. New York: Pergamon Press.
14. Zocoli R, Reichow SL, Zocoli AMF. Otoacousti emissions X Cisplatin: precocious detection of ototoxicity in oncologic patients. Braz J Otorhinolaryngol 2003, 69:222-5.